Volume | 1,652,076 |
|
|||||
News | - | ||||||
Day High | 9.66 | Low High |
|||||
Day Low | 8.85 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.60 | 8.85 | 9.66 | 8.91 | 9.53 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,035 | 1,652,076 | $ 9.20 | $ 15,199,465 | - | 2.41 - 12.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:02 | 4 | $ 9.00 | USD |
Mind Medicine MindMed (MNMD) Options Flow Summary
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.89M | 41.33M | - | 0 | -95.73M | -2.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mind Medicine MindMed News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.89 | 10.94 | 8.85 | 9.89 | 1,229,886 | -1.88 | -17.26% |
1 Month | 10.02 | 12.22 | 8.85 | 10.35 | 2,123,892 | -1.01 | -10.08% |
3 Months | 3.61 | 12.22 | 3.5645 | 8.73 | 2,325,469 | 5.40 | 149.58% |
6 Months | 2.93 | 12.22 | 2.41 | 7.58 | 1,379,261 | 6.08 | 207.51% |
1 Year | 3.56 | 12.22 | 2.41 | 6.63 | 928,429 | 5.45 | 153.09% |
3 Years | 85.3005 | 86.55 | 2.12 | 27.88 | 3,282,237 | -76.29 | -89.44% |
5 Years | 85.3005 | 86.55 | 2.12 | 27.88 | 3,282,237 | -76.29 | -89.44% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |